Notably, EGFR inhibition in NSCLC may result in the emergence of MET, HGF, and ERBB2 amplification, AXL activation, FGF2–FGFR1 loop mutations, IGF1R activation, and fusion events. The gene discussed is MET; the disease is non-small cell lung carcinoma.